Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 6/20 | 0.52 |
| ▸ | NPC1 | O15118 | 4/20 | 0.52 |
| ▸ | TP53 | P04637 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1890213 | 0.85 | ALDH1A1 (0.50) | RAB9ANPC1TP53SMN1; SMN2KMT2A | |
| SCHEMBL1891165 | 0.81 | RAB9A (0.51) | RAB9ANPC1SMN1; SMN2KMT2ALMNA | |
| SCHEMBL1893447 | 0.81 | AHR (0.51) | RAB9ANPC1SMN1; SMN2KMT2ALMNA | |
| SCHEMBL12508094 | 0.79 | RAB9A (0.55) | RAB9ANPC1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL1888774 | 0.79 | RAB9A (0.51) | RAB9ANPC1SMN1; SMN2KMT2AMAPT | |
| SCHEMBL1889947 | 0.79 | RAB9A (0.51) | RAB9ANPC1SMN1; SMN2KMT2AMAPT | |
| SCHEMBL12417679 | 0.79 | MAPT (0.51) | RAB9ANPC1TP53SMN1; SMN2KMT2A | |
| SCHEMBL1886903 | 0.76 | RAB9A (0.48) | RAB9ANPC1SMN1; SMN2KMT2AMAPT | |
| SCHEMBL12417686 | 0.75 | RAB9A (0.53) | RAB9ANPC1TP53SMN1; SMN2KMT2A | |
| SCHEMBL1891491 | 0.75 | SMN1; SMN2 (0.51) | RAB9ANPC1SMN1; SMN2KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1887002-B1 | CARBOXAMIDE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL CO (JP) | 2015-08-26 | — | — | EP | disclosed |
| US-8304437-B2 | Carboxamide compound and use of the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-11-06 | — | — | US | disclosed |
| US-8304437-B2 | Carboxamide compound and use of the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-11-06 | — | — | US | disclosed |
| US-8304437-B2 | Carboxamide compound and use of the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-11-06 | — | — | US | disclosed |
| US-20110172276-A1 | CARBOXAMIDE COMPOUND AND USE OF THE SAME | ARIMORI SADAYUKI | 2011-07-14 | — | — | US | disclosed |
| US-20110172276-A1 | CARBOXAMIDE COMPOUND AND USE OF THE SAME | ARIMORI SADAYUKI | 2011-07-14 | — | — | US | disclosed |
| US-20110172276-A1 | CARBOXAMIDE COMPOUND AND USE OF THE SAME | ARIMORI SADAYUKI | 2011-07-14 | — | — | US | disclosed |
| US-7935716-B2 | Carboxamide compound and use of the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-05-03 | — | — | US | disclosed |
| US-7935716-B2 | Carboxamide compound and use of the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-05-03 | — | — | US | disclosed |
| US-7935716-B2 | Carboxamide compound and use of the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-05-03 | — | — | US | disclosed |
| US-20090076063-A1 | Carboxamide compound and use of the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-03-19 | — | — | US | disclosed |
| US-20090076063-A1 | Carboxamide compound and use of the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-03-19 | — | — | US | disclosed |
| US-20090076063-A1 | Carboxamide compound and use of the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-03-19 | — | — | US | disclosed |
| EP-1887002-A1 | CARBOXAMIDE COMPOUND AND USE THEREOF | Sumitomo Chemical Company, Limited (JP) | 2008-02-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076063-A1 | Carboxamide compound and use of the same | CBR3, SIRT2, SIRT1 | RAB9A 1024/4885NPC1 1710/4885TP53 3956/4885 |
| US-20110172276-A1 | CARBOXAMIDE COMPOUND AND USE OF THE SAME | CBR3, SIRT2, SIRT1 | RAB9A 1024/4885NPC1 1710/4885TP53 3956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.